Press Releases

Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million , a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7 Million ( $0.22 per basic and $0.20 per diluted share), which Includes a One Time Charge of $4.1 Million

CORAL GABLES, Fla. , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it

Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET CORAL GABLES, Fla. , Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel

FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. CORAL GABLES, Fla. , Sept. 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and

CORAL GABLES, Fla. , Sept. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that

CORAL GABLES, Fla. , Aug. 24, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced

Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million , a 57.7% YoY Increase Cash and Short-Term Investments at June 30, 2022 were $220.8 Million , with No Funded Debt Completed Acquisition of Ruzurgi® U.S. and Mexico Commercial Rights Advanced Plans to Diversify Portfolio and

The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET CORAL GABLES, Fla. , July 26, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and

As Part of the Settlement, Catalyst has Acquired Certain of Jacobus’ Intellectual Property Rights, Including the U.S. and Mexico Rights to Ruzurgi® CORAL GABLES, Fla. , July 12, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage

CORAL GABLES, Fla. , May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that